Posted by Michael Wonder on 17 Sep 2025
FDA grants fast track designation to Corbus Pharmaceuticals’ nectin-4 targeting ADC CRB-701 in head and neck squamous cell carcinoma
16 September 2025 - Corbus Pharmaceuticals announced today that the US FDA has granted fast track designation to CRB-701 for the treatment of recurrent or metastatic head and neck squamous cell carcinoma previously treated with platinum-based chemotherapy and an anti-PD(L)-1 therapy.
A fast track designation for relapsed or refractory metastatic cervical cancer was granted by the FDA in December 2024.
